Press Releases Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Delayed Nasdaq Other stock markets 03:59:11 2024-05-09 pm EDT			5-day change	1st Jan Change
25.99 ^USD	+1.17%		-0.04%	+95.41%

May. 02	Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 02	GL
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	Mar. 27	GL
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	Mar. 27	GL
Dyne Therapeutics Announces CEO Transition	Mar. 25	GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	Mar. 13	GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	Mar. 13	AQ
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Mar. 05	GL
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Mar. 05	AQ
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Feb. 14	GL
Dyne Therapeutics to Present at February Investor Conferences	Feb. 01	GL
Dyne Therapeutics to Present at February Investor Conferences	Feb. 01	AQ
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	Jan. 11	GL
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	Jan. 11	AQ
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 05	GL
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock	Jan. 04	GL
Dyne Therapeutics Announces Proposed Public Offering of Common Stock	Jan. 03	GL
Dyne Therapeutics Announces Proposed Public Offering of Common Stock	Jan. 03	AQ
Dyne Therapeutics : ACHIEVE and DELIVER Clinical Data Update Presentation	Jan. 03	PU
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases	Jan. 03	GL
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials	Jan. 02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Press Releases

Filters